UK registry data links cannabis to arthritis relief

Observational evidence published in Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders suggests that long-term use of medical cannabis preparations offers safe, effective relief for individuals suffering from inflammatory arthritis. The findings highlight significant gains in patient-reported outcomes over a two-year period.

Study methodology and scope

A team of British researchers evaluated the impact of botanical cannabis, oil extracts, and topical ointments on 192 patients experiencing pain associated with inflammatory arthritis. These participants were enrolled in the UK Medical Cannabis Registry, a system where healthcare specialists can prescribe cannabis-based medicinal products to patients who have not responded to conventional medications.

The study tracked changes from baseline in patient-reported outcomes at intervals of one, three, six, 12, 18, and 24 months. This longitudinal approach allowed investigators to assess the durability of therapeutic effects across multiple follow-up periods.

Patient outcomes and safety profile

Investigators noted marked improvements in pain levels, sleep quality, and overall quality of life among the cohort. Adverse events linked to cannabis therapy were generally mild, with fatigue and dry mouth being the most commonly reported issues.

“All pain-specific measures showed improvements at each follow-up period,” the study’s authors concluded. They further observed concurrent enhancements in health-related quality of life (HRQoL). Fewer than 15 percent of participants reported adverse events throughout the study period, indicating that cannabis-based medical preparations (CBMPs) were well-tolerated.

The authors stated that these results lend support for ongoing evaluation of CBMPs and underscore the need for randomized clinical trials (RCTs) for this medication class regarding inflammatory arthritis-associated chronic pain.

Broader registry context

This analysis is part of a wider body of observational research utilizing data from the UK Medical Cannabis Registry. Other studies assessing cannabis product usage within the same registry have reported benefits for patients diagnosed with various conditions, including treatment-resistant epilepsy, cancer-related pain, anxiety, hypermobility disorders/Ehlers-Danlos syndrome, endometriosis, inflammatory bowel disease, insomnia, migraine, multiple sclerosis, osteoarthritis, and substance use disorders.

The full text of the study, titled “UK Medical Cannabis Registry: An updated analysis of inflammatory arthritis,” is available in Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. Additional information on cannabis and arthritis can be found in NORML’s publication, Clinical Applications for Cannabis & Cannabinoids.